Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China

• Published in: Diagnostic pathology 2019-07, Vol.14 (1), p.74-74, Article 74
• Main Authors: Huang, Meiling, Yan, Changjiao, Xiao, Jingjing, Wang, Ting, Ling, Rui
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Age; Aged; Amino Acid Substitution; BRAF V600E mutation; Cancer; Cancer metastasis; Cancer research; Carcinoma; Care and treatment; Co-mutations; Coexistence; Confidence intervals; Deoxyribonucleic acid; Development and progression; DNA; Female; Gene mutation; Genes; Genetic aspects; Genetic research; GTP Phosphohydrolases - genetics; Health aspects; Humans; Identification and classification; Lesions; Lymph nodes; Lymphatic Metastasis; Lymphatic system; Male; Medical prognosis; Medical research; Membrane Proteins - genetics; Metastases; Metastasis; Middle Aged; Mortality; Mutation; Nodes; NRAS mutation; Papillary thyroid cancer; Papillary thyroid carcinoma; Pathology; Patients; Promoter Regions, Genetic; Proto-Oncogene Proteins B-raf - genetics; Radiation therapy; Radiotherapy; Recurrence (Disease); Regression analysis; Retrospective Studies; Risk analysis; Risk factors; Statistical analysis; Telomerase; Telomerase - genetics; TERT mutation; Thermal cycling; Thyroid; Thyroid cancer; Thyroid Cancer, Papillary - genetics; Thyroid Cancer, Papillary - pathology; Thyroid diseases; Thyroid Neoplasms - genetics; Thyroid Neoplasms - pathology; Tumors; Young Adult
• ISSN: 1746-1596; 1746-1596
• DOI: 10.1186/s13000-019-0849-6

To determine the relevance of the single or combination mutations of BRAF V600E, TERT, and NRAS genes and the clinicopathologic relationship in papillary thyroid cancer (PTC). Patients with PTC were enrolled into the study between February 2018 and April 2019. Based on the number of mutant genes, we classified the participants into single BRAF V600E mutation group, double mutations group and no mutation group. Single factor and multiple logistic regression analyses were applied to explore the independent factors. Review Manager 5.3 was used for meta-analysis to review the clinical efficacy of gene co-mutations. Finally, 483 patients were enrolled into the study and 419 (86.7%) of them harbored BRAF V600E mutation. TERT or NRAS mutation was likely to coexist with BRAF V600E mutation in PTC. BRAF V600E and NRAS promoter co-mutations was identified in 6 patients, with a prevalence of 1.2%. Prevalence of BRAF V600E and TERT coexistence in PTC was 2.1%. Significant differences were found among age, pathology, multifocality, bilateral lesions, lymph node metastasis, and 131I radiotherapy, P